The $35 Billion Carrot: Why Ryan Cohen Has to Swing

The trade is not "GME is a good retailer." It's that a man with a $24B carrot and no salary is the most asymmetrically deal-motivated CEO in public markets, with $5.2B of net cash to deploy.

The single most common mistake in bullish GME writeups is quoting the $9B gross cash headline without netting the converts. We are not doing that.

Fiscal year ended January 31, 2026 (10-K filed 2026-03-24):

Convert terms: 2030s — $1.5B, 0% coupon, conv. price $29.85, first call 2028-04-06. 2032s — $2.25B, 0% coupon, conv. price $28.91, first call 2029-06-20. Remaining ~$450M in smaller tranches rolls to the $4.2B aggregate in the debt footnote. Conservative net-cash treatment.

Shares & per-share: 448.3M basic → $11.56 net cash/share. Fully-diluted post-conversion 576.4M → $8.99/share.

FY25 performance: Operating CF $614.8M, capex ($17.5M), FCF $597.3M, net income $418.4M (vs. $131.3M FY24), interest income alone $271.5M.

Implication. At $23.32, market cap ~$10.45B. Subtract $5.18B net cash → paying ~$5.27B for a retailer that generated $597M of FCF (~8.8x). Not meme-stock pricing. The premium to book is almost entirely option value on Cohen's next move.

Honest red flags: (1) $131.6M FY25 loss on BTC covered-call strategy — the treasury book can whipsaw. (2) Core retail revenue fell 5% YoY ($3.63B vs. $3.82B) — turnaround is margin, not top-line. (3) $4.2B converts dilute ~32% if fully exercised. (4) Investment Committee has broad discretion on sub-material deployments.

From the January 6, 2026 8-K and press release:

Cohen's existing stake: ~42.1M shares (9.3%). In January 2026 he bought 1.0M additional shares at ~$21.12–21.60 — a CEO with no cash comp voluntarily added ~$21M of personal capital two weeks after the grant. Form 4s on EDGAR.

The asymmetry. Top hurdle is $100B market cap / $10B cumulative EBITDA — roughly a 10x move from today. Intrinsic value at the moment the cap touches $100B: pre-exercise basic ≈ $223/share × 171.5M options ≈ $34.7B; post-exercise diluted ≈ $161/share ≈ $24B. We use the conservative ~$24B. Versus his downside (opportunity cost of a $10–25M CEO salary elsewhere), that's a ~1,000:1 payoff ratio. He literally cannot afford to sit still.

Governance risks we won't paper over:

Cohen's public criteria: publicly traded, consumer, undervalued, durable, sleepy management. We screened US consumer/retail, EV $2–15B (fundable with cash + partial stock), profitable or near-profitable, low insider lock-ups. Ruled out recent take-privates, bankruptcies, founder-blocked names, and cash-burners.

1. Kohl's (KSS) — the single most plausible deal. Market cap ~$1.5B, EV ~$1.9B. GME could fund the entire acquisition in cash with $3B+ left over. 1,200 stores, ~90% of footprint profitable, insider ownership <1%, multi-year sleepy board. Apply Chewy-style SG&A rationalization — a $500M EBITDA uplift takes combined EBITDA from ~$800M to ~$1.3B. At 10x, that's ~$5B of EV added, roughly a double on the KSS equity check and meaningful contribution toward Tranche 1 ($20B cap / $2B EBITDA).

2. Macy's (M). ~$4.5B mkt cap, $9.5B EV. Iconic brand, real-estate optionality, Spring turnaround begun. Larger and more expensive; requires stock as partial currency. Cohen would be accelerating an executing plan rather than waking the dead.

3. Bath & Body Works (BBWI). ~$3.7B mkt cap, $8.7B EV. Best gross-margin profile (~35%+), durable fragrance moat, Wexner non-blocking 17%. Cleanest "Berkshire permanent-holding" fit but more expensive per dollar of EBITDA.

Wildcard: Newell Brands (NWL) at $1.65B market cap — Cohen could buy it entirely in cash and break it up by brand.

Important caveat. Educated triangulation, not a leak. A non-consumer pivot is possible. The trade thesis does not depend on which target — it depends on the incentive structure that forces a deal.

Illustrative, not prescriptive. The structures below are examples a reader with appropriate account, risk tolerance, and horizon might evaluate. Not recommendations. Options are risky, can expire worthless, require approval levels many retail accounts do not have. Consult a licensed advisor.

Why options, not stock? The catalyst is binary, timing is unknown (weeks or 18+ months), and long-dated options give capped downside with asymmetric upside that matches Cohen's own payoff structure.

Live IV snapshot (2026-04-13): 30d realized vol ~78%, 90d ~72%, ATM IV front-month ~58%, Jan 2027 LEAPS ~50%, 25d put skew rich by ~23–26 vol points (downside priced more expensive than upside — long calls relatively cheap). Short interest ~16% of float; borrow 0.39%. No imminent squeeze mechanics.

Strikes/premiums representative of Apr 13 quotes. Re-verify live before trading.

Cost ~$1.85/contract ($185 per 100 shares). Breakeven ~$26.85. Max loss $185 (100% of premium). Scenarios: no deal, drifts to $18 → −$185. Deal announced, stock to $40 → ~+$1,315 (~707%). Grand-slam, stock to $75 → ~+$4,815 (~2,600%). Why: 281 days survives the timing problem; ~11.5x leverage vs. stock; defined max loss lets retail size responsibly.

Net debit ~$1.25. Max loss $125; max profit $875. Breakeven ~$21.25. Why: Cheaper than LEAPS, caps upside but also caps theta bleed. Appropriate for capital-constrained readers. Loses the grand-slam tail.

Risk disclosures: Theta decay ~$0.35–0.60/contract/day on long calls, accelerating into expiry — set a hard reassessment date. IV crush on announcement can collapse vol 30–50 points; plan to sell into the spike. Gap risk ±20% non-fundamental — position ≤1% of portfolio retail, ≤0.5% if portfolio <$50k. Vote risk: if the April Cohen-LTI vote fails, the asymmetric-carrot thesis partially unwinds. Do not use leverage.

Thesis in one sentence: GME's CEO has the largest at-risk performance option grant in US retail history, a $5B+ war chest, public commitment to a transformational consumer acquisition, and nine years of option runway — we want cheap, defined-risk, long-dated upside exposure to whatever he does next.

Sizing:

Catalysts: Shareholder vote on Cohen's LTI (Mar/Apr 2026, binary risk); Q1 FY26 earnings (late May/early June); any new Cohen 13D/A or Form 4; a tape move above $25 with volume.

Exit the trade if: the vote fails; Cohen resigns or is removed; a deal is announced and executed poorly (premium >30%, lockups >20%); the reference price is violated below ~$19.50 on negative earnings.

The Liew Letter is published by SoKat Consulting LLC. Educational and informational only; not personalized investment advice or a recommendation to buy or sell any security. No representation is made that any reader will achieve similar results. Consult your own licensed financial advisor. Options trading involves substantial risk and is not suitable for all investors. As of dispatch, the author and SoKat Consulting LLC hold no position in GME securities or derivatives. Past performance is not indicative of future results.

Educational research, not individualized investment advice. The author and SoKat Consulting LLC hold no position in GME or its derivatives as of dispatch. Options carry risk of total loss of premium. Do not risk capital you cannot afford to lose on a name with documented ±20% gap history. All fundamentals verified against primary SEC filings.